Anhedonia Clinical Trial
— MoNSSOfficial title:
Treating Negative Symptoms of Schizophrenia With a Motive-specific Intervention: A Randomised Controlled Trial
The aim of this study is to test a therapeutic intervention to reduce negative symptomatic among schizophrenia patients. Since the intervention can take place within an inpatient stay, it is a short intervention. Three appointments are made with the patients within two weeks. With an adaptation of the Autobiographical Memory Test (AMT) participants will be asked to recall events from the past and to imagine future events. Patients are additionally asked to complete tasks between the sessions. One pre- and one post-measurement of negative symptoms, motives, level of functioning, hope for recovery and other co-variables are part of the study. A follow-up appointment four weeks later is intended to provide information on the longer-term impact.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | June 30, 2022 |
Est. primary completion date | December 31, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Informed Consent as documented by signature - Male and female inpatients between 18 and 65 years of age - ICD-10 diagnosis of psychosis (F2) - Clinical relevant negative symptoms - Ability to judge with regard to decisions on study participation - Fluent in German and able to understand the instructions Exclusion Criteria: - Florid positive psychotic symptoms (measured with PANSS; that is any positive-subscale item score higher than five) - Post-schizophrenic depression (ICD: F20.4) - Organic schizophrenia-like disorder (ICD: F0.6) - Known or suspected non-compliance, drug or alcohol abuse during treatment - Cognitive impairments: strongly below average values in cognitive tests - Complete stop or restart of taking antipsychotic medication during the study (dose adjustments are not a reason for exclusion) - Previous enrolment in the current study - Enrolment of the investigator, his/her family members, employees and other dependent persons. |
Country | Name | City | State |
---|---|---|---|
Switzerland | Psychiatric University Hospital | Zürich | Zurich |
Lead Sponsor | Collaborator |
---|---|
University of Zurich |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Reduction of negative symptoms measured with the Brief Negative Symptom Scale (BNSS) | The primary outcome criterion is the change and expected reduction of the severity of the negative symptoms in schizophrenia patients before and after the three-week motive-specific intervention. We compare the change of severity between the patients of the intervention group and those in the control group. Negative symptoms are measured with the Brief Negative Symptom Scale (BNSS) and items are rated on a 7-point-scale (0 = absent, 6 = severe). | Baseline | |
Primary | Long-term Reduction of negative symptoms measured with the Brief Negative Symptom Scale (BNSS) | Another primary outcome criterion is the change of the severity of the negative symptoms in schizophrenia patients who have received the motive-specific intervention compared to the control group patients in a follow-up appointment four weeks after termination of the intervention. Negative symptoms are measured with the Brief Negative Symptom Scale (BNSS) and items are rated on a 7-point-scale (0 = absent, 6 = severe). | 4 weeks after end of the psychotherapeutic intervention | |
Secondary | Correlation between the severity of negative symptoms and explicit motives measured with the Questionnaire for the Zurich Model of Social Motivation | Secondary outcome criterion is the statistical significance and quality of the relationship between negative symptoms (measured with the Brief Negative Symptom Scale; items are rated on a 7-point-scale with 0 = absent and 6 = severe) and explicit reported motives. | Baseline | |
Secondary | Correlation between the severity of negative symptoms and implicit motives measured with the Multi Motive Gitter | Another secondary outcome criterion is the statistical significance and quality of the relationship between negative symptoms (measured with the Brief Negative Symptom Scale; items are rated on a 7-point-scale with 0 = absent and 6 = severe) and implicit motives. | Baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05234476 -
Behavioral Activation Plus Savoring for University Students
|
N/A | |
Enrolling by invitation |
NCT06035562 -
Promoting Positive Emotional Functioning in Police and Military Populations
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Completed |
NCT03043560 -
Study to Treat Major Depressive Disorder With a New Medication
|
Phase 2 | |
Withdrawn |
NCT05507385 -
Imagine a Brighter Future: An Intervention to Improve Positive Emotions in Young People
|
N/A | |
Completed |
NCT05383248 -
Computational Cognitive Training To Boost Reward Responsiveness In Anhedonic Patients
|
N/A | |
Suspended |
NCT03715400 -
Mobile Virtual Positive Experiences for Anhedonia
|
N/A | |
Recruiting |
NCT05240352 -
Developing Brain Imaging Analysis Expertise for Personalizing Transcranial Electric Stimulation in Anhedonia Treatment of Patients With Bipolar Depression
|
N/A | |
Recruiting |
NCT03915613 -
Brain Insulin Resistance in Mood Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT04121091 -
Pramipexole to Target "Anhedonic Depression"
|
Phase 2 | |
Completed |
NCT03939676 -
Evaluating Motivation and Reward Mechanisms and Brain Substrates in Adults With Obesity
|
||
Enrolling by invitation |
NCT06285474 -
Investigating LIFUP in Anhedonic Depression
|
N/A | |
Recruiting |
NCT05870501 -
Synaptic Imaging and Network Activity in Treatment Resistant Depression
|
N/A | |
Active, not recruiting |
NCT03848715 -
Sleep and Healthy Aging Research on Depression for Younger Women
|
Phase 1 | |
Completed |
NCT05165394 -
Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD
|
Phase 2 | |
Completed |
NCT04647019 -
The Effects of Wild Blueberries on Depressive Symptoms in Young Adults
|
N/A | |
Recruiting |
NCT06075771 -
Dopaminergic Therapy for Anhedonia - 2
|
Phase 4 | |
Completed |
NCT02958228 -
The Effect of Computerized Cognitive Training on Mood and Thinking Style Amongst Patients in Inpatient Settings
|
N/A | |
Recruiting |
NCT05991713 -
Geolocation Positional System (GPS) Experience
|
N/A | |
Completed |
NCT05084924 -
Investigating the Causal Role of Prefrontal Control in Decision-making in Patients With Anhedonia
|
N/A |